105 related articles for article (PubMed ID: 1167560)
1. Effects of human C 1 inhibitor on complement-mediated human leukocyte chemotaxis.
Smith CW; Hollers JC; Bing DH; Patrick RA
J Immunol; 1975 Jan; 114(1 Pt 1):216-20. PubMed ID: 1167560
[TBL] [Abstract][Full Text] [Related]
2. Complement-mediated release of histamine from human leukocytes.
Grant JA; Dupree E; Goldman AS; Schultz DR; Jackson AL
J Immunol; 1975 Mar; 114(3):1101-6. PubMed ID: 46261
[TBL] [Abstract][Full Text] [Related]
3. [Studies on the mobilities of granulocytes and the chemotactic factor production by human mononuclear cells (author's transl)].
Nakayama M
Hokkaido Igaku Zasshi; 1981 Mar; 56(2):217-31. PubMed ID: 7327510
[TBL] [Abstract][Full Text] [Related]
4. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
[TBL] [Abstract][Full Text] [Related]
5. The roles of IgG, IgM rheumatoid factor, and their complexes in the induction of polymorphonuclear leukocyte chemotactic factor from complement.
Wagner T; Abraham G; Baum J
J Clin Invest; 1974 Jun; 53(6):1503-11. PubMed ID: 4133792
[TBL] [Abstract][Full Text] [Related]
6. Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells.
Orr FW; Varani J; Kreutzer DL; Senior RM; Ward PA
Am J Pathol; 1979 Jan; 94(1):75-83. PubMed ID: 569981
[TBL] [Abstract][Full Text] [Related]
7. Complement C4-derived monocyte-directed chemotaxis-inhibitory factor. A molecular mechanism to cause polymorphonuclear leukocyte-predominant infiltration in rheumatoid arthritis synovial cavities.
Matsubara S; Yamamoto T; Tsuruta T; Takagi K; Kambara T
Am J Pathol; 1991 May; 138(5):1279-91. PubMed ID: 2024711
[TBL] [Abstract][Full Text] [Related]
8. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
[TBL] [Abstract][Full Text] [Related]
9. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation.
Muhlfelder TW; Niemetz J; Kreutzer D; Beebe D; Ward PA; Rosenfeld SI
J Clin Invest; 1979 Jan; 63(1):147-50. PubMed ID: 762243
[TBL] [Abstract][Full Text] [Related]
10. Effects of human complement component 1 inactivator on neutrophil chemotaxis and chemotactic deactivation.
Patrick RA; Hollers JC; Liu DY; Giese BH; Smith CW
Infect Immun; 1980 Jun; 28(3):700-7. PubMed ID: 7399690
[TBL] [Abstract][Full Text] [Related]
11. Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity.
Venge P; Olsson I
J Immunol; 1975 Dec; 115(6):1505-8. PubMed ID: 1184964
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the C5 peptides chemotactic for leukocytes and tumor cells.
Romualdez AG; Ward PA; Torikata T
J Immunol; 1976 Nov; 117(5 Pt.2):1762-6. PubMed ID: 62790
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways.
Gallin JI; Clark RA; Frank MM
Clin Immunol Immunopathol; 1975 Jan; 3(3):334-46. PubMed ID: 1088938
[No Abstract] [Full Text] [Related]
14. Chemotactic responsiveness and random motility of polymorphonuclear leukocytes from patients with progressive systemic sclerosis.
Minta JO; Kovacs EK; Sukenik S; Lee P
J Rheumatol; 1985 Dec; 12(6):1125-8. PubMed ID: 4093918
[TBL] [Abstract][Full Text] [Related]
15. Production of chemotactic activity by guinea pig immunoglobulins following activation of the C3 complement shunt pathway.
Sandberg AL; Snyderman R; Frank MM; Osler AG
J Immunol; 1972 May; 108(5):1227-31. PubMed ID: 5029138
[No Abstract] [Full Text] [Related]
16. Complement inhibitor(s) released by leukocytes. III. Evidence for a "new" C1 inhibitor in the supernatants of short-term cultures of mouse spleen and thymus cells.
Bernard A; Boumsell L; Borsos
J Immunol; 1975 Oct; 115(4):1091-4. PubMed ID: 1176767
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of the chemotactic response of neoplastic cells to a factor derived from the fifth component of complement.
Orr W; Varani J; Ward PA
Am J Pathol; 1978 Nov; 93(2):405-22. PubMed ID: 568888
[TBL] [Abstract][Full Text] [Related]
18. Nonspecific activation of complement factor 5 by isolated Dermacentor andersoni salivary antigens.
Gordon JR; Allen JR
J Parasitol; 1991 Apr; 77(2):296-301. PubMed ID: 2010863
[TBL] [Abstract][Full Text] [Related]
19. Neutropenia induced by systemic infusion of chemotactic factors.
O'Flaherty JT; Showell HJ; Ward PA
J Immunol; 1977 May; 118(5):1586-9. PubMed ID: 858915
[TBL] [Abstract][Full Text] [Related]
20. The effect of a novel C5 inhibitor (K-76 COONa) on tumor cell chemotaxis.
Bumpers HL; Baum J
J Lab Clin Med; 1983 Sep; 102(3):421-7. PubMed ID: 6886523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
